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Why Evidence-Based Guidelines
Are Urgently Needed
Mental, neurological, and substance use
(MNS) disorders are highly prevalent and
are responsible for 14% of the global
burden of disease expressed in disability-
adjusted life years (DALYs) [1]. The
resources that have been provided in
countries to tackle the huge burden are
insufficient, inequitably distributed, and
inefficiently used, which results in a large
majority of people with these disorders
receiving no care at all [2–7]. Even when
available, treatment and care often is
neither evidence-based nor of high quality.
The result is a large treatment gap, with
more than 75% in many low- and middle-
income countries (LAMIC).
In order to reduce the gap, the World
Health Organization (WHO) launched the
Mental Health Gap Action Programme
The Policy Forum allows health policy makers
around the world to discuss challenges and
opportunities for improving health care in their
societies.
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(mhGAP) to scale up services for people
with MNS disorders, especially in LAMIC
[1]. One essential component of mhGAP
is to develop management recommenda-
tions (guidelines) for MNS disorders iden-
tified as conditions of high priority. The
priority conditions included are depres-
sion, psychosis, bipolar disorders, epilepsy,
developmental and behavioural disorders
in children and adolescents, dementia,
alcohol use disorders, drug use disorders,
and self-harm/suicide. The priority con-
ditions were selected because they repre-
sent a large burden [8] in terms of
mortality, morbidity, or disability, have
high economic costs, and are often asso-
ciated with violations of human rights.
Evidence suggests that explicit, evi-
dence-based, cost-effective packages of
interventions can improve the processes
and outcomes of health care when
appropriately implemented. A package
approach is being considered for a wide
variety of health challenges such as the
packages of interventions for family plan-
ning, safe abortion care, and maternal,
newborn, and child health [9]. The recent
grand challenges in global mental health
underline the fact that all interventions
should be evidence-based to provide
programme planners, clinicians, and pol-
icy-makers with effective care packages
[10]. While examples of evidence-based
packages of care for MNS disorders exist
that focus mainly on delivery mecha-
nisms, they did not systematically synthe-
size and appraise the evidence base for
interventions [11]. WHO therefore estab-
lished a Guideline Development Group
(GDG) in 2008 to develop evidence-based
recommendations that adhered to the
Grading of Recommendations Assess-
ment, Development and Evaluation
(GRADE) principles for developing trans-
parent, evidence-based WHO guidelines
[12].
This article presents the management
recommendations for MNS conditions,
with a specific link (below) to the WHO
website where all the background material
may be accessed, including the evidence
profiles and GRADE tables. Disseminat-
ing the recommendations through the
scientific literature is important to gener-
ate feedback from health care profession-
als, policy–makers, and scientists. This will
be helpful for re-defining the challenges
(we may have omitted some important
topics, or we should have addressed some
other topics in a different way); re-
evaluating the synthesized evidence; re-
directing the development of the interven-
tion guide for use in LAMIC; and re-
defining any implementation strategies in
LAMIC (Figure 1). In this article, we use
the term ‘‘mental health’’ as a convenient
label for MNS disorders.
mhGAP Recommendations
WHO recommendations aim to be
based on systematic reviews of the best
available evidence and consideration of
values, preferences, and feasibility issues
from an international perspective and as
reflected in relevant WHO policy docu-
ments and technical tools. Evidence pro-
files were developed for each of the
priority conditions as well as a category
labeled ‘‘other significant emotional or
medically unexplained complaints.’’
Tables 1–8 provide the running title of
the question and the abridged recommen-
dations for each of the conditions. These
recommendations focus on the manage-
ment of MNS disorders in non-specialist
settings in LAMIC. Each recommendation
has a unique identifier—a short form of
the priority condition and a number (e.g.,
DEP 1 for depression question 1). The
detailed evidence profile can be accessed
from the mhGAP Evidence Resource
Centre (http://www.who.int/mental_health/
mhgap/evidence/en/index.html).
Strengths and Limitations of
the Process
Developing recommendations is a com-
plex process that involves systematic
review and assessment of the quality of
evidence and balance of benefits and
harms. In addition, explicit consideration
of other issues such as value judgments,
resource use, and feasibility, which are
major considerations, need to be incorpo-
rated. Developing mhGAP recommenda-
tions within this framework highlighted
several challenging and critical issues,
including difficulties in formulating ques-
tions and rating outcomes, potential re-
producibility and consistency problems,
problems in incorporating observational
evidence when evidence in the form of
randomized trials was not available, and
difficulties in defining how values, prefer-
ences, and feasibility issues should be
considered, as the methodology for these
aspects is much less developed [12].
The mhGAP guidelines highlight issues
where uncertainty or controversy exists or
areas where a change in policy or clinical
practice is needed. Table 9 provides
examples of some areas where the review
of evidence, values, and resource consid-
erations supported the change required in
clinical practice.
One of the most challenging aspects of
the whole process was that while for some
mental health areas the background evi-
dence was quite robust, for others the
conventional way of synthesizing and
evaluating the evidence revealed no or
very poor quality evidence that was
insufficient to make any recommendation.
For example, some psychosocial interven-
tions for individuals with psychosis or
bipolar disorder are backed by few studies
that provide inconclusive results. In such
instances we took advantage of the
GRADE methodology, which clearly rec-
ognizes that in addition to the evidence
base, other aspects that are expected to
inform the recommendations include con-
sideration of values such as protection of
human rights, feasibility and resource use,
and GDG professional experience and
their tacit knowledge. As previously noted,
the added value of GRADE in these
circumstances is that it requires GDG to
transparently report that some recommen-
dations are based on strong values and
weak evidence [12]. By contrast, in other
areas where a substantial amount of
evidence is available, positive recommen-
dations could not be issued due to
Summary Points
N The treatment gap for mental, neurological, and substance use (MNS) disorders
is more than 75% in many low- and middle-income countries.
N In order to reduce the gap, the World Health Organization (WHO) has
developed a model intervention guide within its Mental Health Gap Action
Programme (mhGAP).
N The model intervention guide provides evidence-based recommendations
developed with the Grading of Recommendations Assessment, Development
and Evaluation (GRADE) methodology.
N This article presents the management recommendations for MNS disorders,
with a link to the World Health Organization website where all the background
material may be accessed.
N To our knowledge, this is a first exercise involving such an extensive and
systematic evaluation of evidence in this area.
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considerations on feasibility aspects. For
example, full cognitive behavioural thera-
py may be hardly feasible in many low-
and middle-income settings considering
the training, supervision, and time needed
for this intervention, and taking into
consideration the need for local adapta-
tions. Similarly, drug treatments that
require regular blood checks may not be
recommended in settings where no infra-
structure is available to provide such
checks on a continuous basis.
Another challenging aspect was that
while the main focus of WHO’s mental
health work was to develop recommenda-
tions for health care providers in low- and
middle-income settings, most of the evi-
dence comes from specialist settings of
high-income countries. Despite this, we
developed and applied instructions to
overcome this compelling issue [12];
increasing implementation research in
the contexts where the guidelines should
eventually be applied would seem the best
approach to enhance the applicability of
research findings into practice.
Maintaining and Updating
mhGAP Recommendations
Maintaining and updating evidence-
based recommendations is similarly rele-
vant, as new evidence is continuously
generated and accumulated in the interna-
tional literature. Updating of mhGAP
recommendations will not only be based
on this new evidence, but also on feedback
from health care professionals, policy-
makers, scientists, and public health experts
involved in implementing the guidelines.
We also expect that revisions might include
review of new questions or areas currently
not covered by mhGAP guidelines, which
might be identified as relevant questions to
be addressed. In order to facilitate and
encourage feedback, an electronically ac-
cessible web repository of recommenda-
tions and background material, including
all the evidence profiles that were used to
generate the recommendations, has recent-
ly been developed and will be regularly
maintained and updated (http://www.
who.int/mental_health/mhgap/evidence/
en/index.html). The readers of this article
can also provide their feedback by posting
comments online at PLoS Medicine. WHO
will follow a systematic procedure for
updating the recommendations following
the same strict and transparent methodo-
logical process that was employed for their
initial development.
Guideline Implementation
Issues
Scaling up delivery of interventions and
achieving a desirable level of mental
health care quality requires a dynamic
and collaborative approach. Research
findings that are generated by studies
and trials should guide health care pro-
viders when making decisions in clinical
Figure 1. Steps in the formulation and implementation of the mhGAP Intervention Guide.
doi:10.1371/journal.pmed.1001122.g001
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Table 1. Abridged recommendations for depression (DEP 1–6) and other significant emotional or medically unexplained
complaints (OTH 1–7).
Role of antidepressants and
benzodiazepines
DEP 1. Antidepressants should not be considered for the initial treatment of adults with mild depressive episode. Tricyclic
antidepressants (TCA) or fluoxetine should be considered in adults with moderate to severe depressive episode/disorder.
OTH 2. Neither antidepressants nor benzodiazepines should be used for the initial treatment of individuals with
complaints of depressive symptoms in absence of current/prior depressive episode/disorder.
Duration of antidepressant treatment DEP 2. Antidepressant treatment should not be stopped before 9–12 months after recovery.
Brief, structured,
psychological treatment
DEP 3. Interpersonal therapy and cognitive behavioural therapy (CBT) (including behavioural activation, DEP 4), and problem-
solving treatment should be considered as psychological treatment of depressive episode/disorder in non-specialized health care
settings if there are sufficient human resources (e.g., supervised community health workers). In moderate and severe depression,
problem-solving treatment should be considered as adjunct treatment.
OTH 3. A problem-solving approach should be considered in people with depressive symptoms (in the absence of depressive
episode/disorder) who are in distress or have some degree of impaired functioning.
OTH 1. Psychological treatment based on CBT principles should be considered in repeat adult help seekers with medically
unexplained somatic complaints who are in substantial distress and who do not meet criteria for depressive episode/disorder.
Relaxation training and
physical activity
DEP 5, DEP 6. Relaxation training and advice on physical activity may be considered as treatment of adults with depressive
episode/disorder. In moderate and severe depression, these interventions should be considered as adjunct treatment.
Psychological support
after recent traumatic
event
OTH 4. Psychological debriefing should not be used for recent traumatic event to reduce the risk of post-traumatic
stress, anxiety, or depressive symptoms.
OTH 5. Providing access to support based on the principles of psychological first aid should be considered for people in
acute distress exposed recently to a traumatic event.
Graded self-exposure based on CBT
principles in adults with post-traumatic
stress disorder (PTSD) symptoms
OTH 6. If it is possible to continue to follow up with the patient, graded self-exposure based on the principles of CBT
should be considered in adults with PTSD symptoms.
Psychological treatment based
on CBT principles in people
concerned about prior panic attacks
OTH7. Psychological treatment based on CBT principles should be considered as treatment of people concerned about
prior panic attacks.
doi:10.1371/journal.pmed.1001122.t001
Table 2. Abridged recommendations for epilepsy and seizures (EPI 1–12).
Management of acute
convulsive seizures and
status epilepticus
EPI 1. Intravenous (IV) access not available: Rectal diazepam should be administered. Intramuscular (IM) administration of diazepam is
not recommended because of erratic absorption. IM phenobarbital may also be considered when rectal use of diazepam is not
possible due to medical or social reasons.
EPI 2. IV access available: An IV benzodiazepine (lorazepam or diazepam) should be administered (if available, lorazepam is preferred over
diazepam). For sustained control or if seizures continue, IV phenobarbital or phenytoin should be administered.
Management of febrile
seizures
EPI 3. In simple febrile seizures, local standards for diagnosis and management of fever (including Integrated Management of
Childhood Illnesses) should be followed and children should be observed for 24 hours. Children with complex febrile seizures (CFS)
should be observed within an inpatient setting. Investigations such as blood tests and lumbar puncture to determine the presence of
underlying etiology is recommended as appropriate.
Prophylactic intermittent diazepam during febrile illness may be considered in the treatment of recurrent or prolonged CFS but not for
simple febrile seizures.
Diagnosis of convulsive
epilepsy
EPI 4. Non-specialist health care providers can be trained to recognize and diagnose convulsive epilepsy. Such training should be provided.
EPI 5 & EPI 6. Electroencephalography (EEG) and neuroimaging should not be used routinely for diagnosis of epilepsy and starting
treatment in non-specialized health care settings in LAMIC. If required for formulation of etiological diagnosis, EEG and neuroimaging
should be done in specialized facilities under optimum technical conditions and with adequate expertise for interpretation of the data
and results.
Antiepileptic drugs EPI 7. In convulsive epilepsy, monotherapy with any of the standard antiepileptic drugs (carbamazepine, phenobarbital, phenytoin, and valproic
acid) should be offered. Given the acquisition costs, phenobarbital should be offered as a first option if availability can be assured. If available,
carbamazepine should be preferentially offered to children and adults with partial onset seizures.
EPI 8. Antiepileptic drugs should not be routinely prescribed to adults and children after a first unprovoked seizure.
EPI 9. Discontinuation of antiepileptic drug treatment should be considered after 2 seizure-free years. The decision to withdraw or
continue antiepileptic drugs in a seizure-free patient should be made after consideration of relevant clinical, social, and personal
factors and with the involvement the patient and the family.
Psychological
interventions
EPI 10. Information and advice on avoiding high-risk activities and first aid relevant to the person and family members should be
routinely given. Psychological treatments such as relaxation therapy, treatments based on cognitive behavioural therapy principles,
psychoeducational programmes, and family counselling may be considered as adjunctive treatment.
Management of epilepsy
in women of childbearing
age
EPI 11. Women with epilepsy should have seizures controlled as well as possible with antiepileptic drug monotherapy at minimum
effective dose. Valproic acid should be avoided if possible. Antiepileptic drug polytherapy should be avoided.
Folic acid should routinely be taken when they are on antiepileptic drugs. Standard breast feeding recommendations remain
appropriate for the antiepileptic drugs included in this review (phenobarbital, phenytoin, carbamazepine, and valproic acid).
Management of epilepsy
and associated intellectual
disability
EPI 12. People with intellectual disability and epilepsy should have access to the same range of investigations and treatment as the rest of
the population. The drug of choice depends on the type of seizure and should be individualized. When available, consider either valproic
acid or carbamazepine instead of phenytoin or phenobarbital due to lower risk of behavioural adverse effects.
CFS, complex febrile seizures; EEG, electroencephalography; IM, intramuscular; IV, intravenous.
doi:10.1371/journal.pmed.1001122.t002
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Table 3. Abridged recommendations for psychosis and bipolar disorders (PSY 1–13).
Psychosis
Role of antipsychotic medicines PSY 1. Haloperidol or chlorpromazine should be routinely offered. Second-generation
antipsychotics (with the exception of clozapine) may be an alternative if availability
can be assured and cost is not a constraint. For individuals who do not respond to
antipsychotic medicines, clozapine may be considered by non-specialist health care
providers, preferably under the supervision of mental health professionals, only if
routine laboratory monitoring is available.
Use of two or more antipsychotic
medications concurrently
PSY 2. Routinely, one antipsychotic should be prescribed at a time. For individuals
who do not respond to antipsychotic medicines (using one medicine at a time),
antipsychotic combination treatment may be considered by primary health care
professionals, preferably under the supervision of mental health professionals with
close clinical monitoring.
Length of antipsychotic treatment in
individuals with a first psychotic episode
PSY 3. Antipsychotic treatment should be continued for at least 12 months after the
beginning of remission.
Antipsychotic withdrawal in individuals with
long term and/or recurrent illness
PSY 4. In individuals stable for several years on antipsychotic treatment, withdrawal
may be considered keeping in mind the increased risk of relapse, possible adverse
effects of medicines, and individual preferences in consultation with the family. This
decision should be made preferably in consultation with a mental health professional.
Role of depot antipsychotic medication PSY 5. Individuals on long-term antipsychotic treatment should be given adequate
information and encouraged to make a choice between oral and depot preparations,
especially with the view to improve adherence.
Role of anticholinergic medications in
preventing or reducing extrapyramidal side-effects
PSY 6. Anticholinergics should not be used routinely for preventing extrapyramidal
side effects. Short-term use may be considered only in individuals with significant
extrapyramidal side effects when dose reduction and switching strategies have
proven ineffective, or when these side effects are acute or severe.
Bipolar disorder
Role of medicines in the manic phase PSY 7. Haloperidol is recommended in individuals with bipolar mania. Second-
generation antipsychotics may be considered as an alternative if availability can be
assured and cost is not a constraint. Lithium, valproate, or carbamazepine should be
offered to individuals with bipolar mania. Treatment with lithium should be initiated
only in those settings where personnel and facilities for close clinical and laboratory
monitoring are available.
Role of medicines in the maintenance phase PSY 8. Lithium or valproate should be used for the maintenance treatment of bipolar
disorder. Maintenance treatment should continue for at least 2 years after the last
episode of bipolar disorder. Decision to continue maintenance treatment after 2 years
should preferably be done by a mental health specialist.
Role of medicines in the depressive phase PSY 9. Antidepressant medicines, always in combination with a mood stabilizer
(lithium or valproate), may be considered in the treatment of moderate or severe
depressive episodes of bipolar disorder. Selective serotonin reuptake inhibitors (SSRI;
fluoxetine) should be preferred to tricyclic antidepressants (TCA).
Psychosocial interventions
Role of psychoeducation PSY 10. Psychoeducation should be routinely offered to individuals with psychotic
and bipolar disorders and their family members/caregivers. Cognitive behavioural
therapy and family interventions can be considered as an option if adequately trained
professionals are available.
Role of psychosocial strategies PSY 11. Psychosocial interventions to enhance independent living and social skills
should be considered for people with psychotic and bipolar disorders and their
families/caregivers. Social skills training may be considered as an option, in
association with other psychosocial interventions. Facilitation of supported housing/
assisted living facilities as well as independent living facilities may be considered as
an option, with careful consideration to patients’ functional capacity and need for
stability and support.
Role of vocational and
economic inclusion
PSY 12. Non-specialist health care providers should facilitate opportunities for people
with severe mental, neurological, and substance use disorders and their families/
caregivers to be included in economic activities appropriate to their social and
cultural environment, using formal and non-formal systems that may be available.
Facilitation of supported employment may be considered as an option if they have
difficulty in obtaining or retaining normal employment.
Role of strategies aimed at
improving community attitudes
PSY 13. Activities aimed at improving community attitudes towards people with
mental, neurological, and substance use conditions (e.g., anti-stigma campaigns) may
be considered for implementation.
doi:10.1371/journal.pmed.1001122.t003
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Table 4. Abridged recommendations for self-harm and suicide (SUI 1–9).
Role of asking about thoughts,
plan or act of self-harm
SUI 1. Individuals over 10 years of age suffering from any of the other priority conditions, or who present with chronic
pain or acute emotional distress associated with current interpersonal conflict, recent loss, or other severe life event,
should be asked about thoughts or plans of self-harm in the last month or acts of self-harm in the last year at initial
assessment and periodically as required.
Role of removing means for
self-harm/suicide from a person
SUI 2. The individual, family, and relevant others should be advised to restrict access to the means for self-harm (e.g., pesticides
and other toxic substances, medication, firearms) as long as the individual has thoughts, plans, or acts of self-harm.
Role of contact for persons with
thoughts, plans or acts of self-harm
SUI 3. Regular contact (telephone contact, home visits, letter, contact card, brief intervention and contact) with the
non-specialized health care provider is recommended for persons with acts of self-harm in the last year, and should be
considered for persons with thoughts or plans of self-harm in the last month.
Role of a problem solving approach SUI 4. A structured problem-solving approach should be considered as a treatment for persons with acts of self-harm in
the last year, if there are sufficient human resources.
Role of social support SUI 5. Use of social support (from available informal and/or formal community resources) should be facilitated for
persons with thoughts or plans of self-harm in the last month or acts of self-harm in the last year.
Role of hospitalization SUI 6. Hospitalization in non-specialized services of general hospitals with the goal of preventing acts of self-harm is
not routinely recommended for persons with self-harm. If imminent risk of self-harm is a concern, urgent referral to a
mental health service should be considered. However, if such a service is not available, family, friends, concerned
individuals, and other available resources should be mobilized to ensure close monitoring.
Role of reducing access to means
of suicide at the population level
SUI 7. Restricting access to means of self-harm (such as pesticides, firearms, high places) is recommended.
Role of reducing the availability
of alcohol
SUI 8. Policies to reduce harmful use of alcohol should be developed as a component of a comprehensive suicide
prevention strategy, particularly within populations with high prevalence of alcohol use.
Role of responsible and
deglamourized media reporting
SUI 9. Responsible media reporting of suicide (such as avoiding language which sensationalizes or normalizes suicide or
presents it as a solution to a problem, avoiding pictures and explicit description of the method used, and providing
information about where to seek help) is recommended.
doi:10.1371/journal.pmed.1001122.t004
Table 5. Abridged recommendations for dementia (DEM 1–10).
Role of acetylcholinesterase
inhibitors and memantine
DEM 1 & DEM 2. Acetylcholinesterase inhibitors or memantine should not be considered routinely for people with dementia in non-
specialist health settings in LAMIC. They may be considered where adequate support and supervision by specialists is available.
Consideration should be given to adherence and monitoring of adverse effects, which generally requires the availability of a carer.
Role of medicines including
antipsychotics for behavioural
and psychological symptoms
of dementia
DEM 3. Thioridazine, chlorpromazine, or trazodone should not be used for the treatment of behavioural and psychological
symptoms of dementia.
Haloperidol and atypical antipsychotics should not be used as first-line management. Where there is clear and imminent risk of
harm with severe and distressing symptoms, their short-term use may be considered, preferably in consultation with specialist.
Role of antidepressants DEM 4. In people with dementia with moderate or severe depression, use of selective serotonin reuptake inhibitors may be
considered. In case of non-response after at least 3 weeks, they should preferably be referred to a mental health specialist for
further assessment and management.
Cognitive and psychosocial
interventions
DEM 5. Cognitive interventions applying principles of reality orientation, cognitive stimulation, and/or reminiscence therapy
may be considered in the care of people with dementia. Health care providers should be trained for delivering these
interventions and family members should be involved in delivery of these interventions.
Diagnosis of dementia DEM 6. Non-specialist health care providers should seek to identify possible cases of dementia in the primary health care setting
and in the community after appropriate training and awareness raising. Brief informant assessment and cognitive tests should
be used to assist in confirming these cases. For a formal dementia diagnosis, a more detailed history, medical review, and
mental state examination should be carried out to exclude other common causes of cognitive impairment and decline.
DEM 7. People with dementia and their family members should be told of the diagnosis subject to their wishes in this regard,
keeping in mind cultural sensitivities and employing some preparatory work to determine their preferences. It should be
accompanied with relevant information appropriate to culture and understanding of people, and with a commitment of
ongoing support and care that can be provided by health and other services.
Role of a medical review DEM 8. People with dementia should receive an initial and a regular medical review (at least every 6 months) and appropriate care.
Interventions for carers of
people with dementia
DEM 9. Psychoeducational interventions should be offered to family and other informal carers of people with dementia at the
time when diagnosis is made. Training of carers involving active carer participation (e.g., role playing of behavioural problem
management) may be indicated later in the course of illness for carers who are coping with behavioural symptoms in people
with dementia. Carer psychological strain should be addressed with support, counselling, and/or cognitive behaviour
interventions. Depression in carers should be managed according to the recommendations for depression.
DEM 10. Where feasible, home-based respite care may be encouraged for carers of people with dementia.
doi:10.1371/journal.pmed.1001122.t005
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Table 6. Abridged recommendations for alcohol use disorders (ALC 1–6).
Screening and brief
interventions
ALC 1. Screening for hazardous and harmful alcohol use should be conducted, using a validated instrument that can be easily
incorporated into routine clinical practice (e.g., AUDIT-3, AUDIT-C, ASSIST). In settings in which screening is not feasible or
affordable, practitioners should explore alcohol consumption in their patients when relevant.
Patients with a hazardous and harmful alcohol use should receive a brief intervention.
Patients who on screening are identified as having dependence should be managed according to the recommendations in
the section on alcohol dependence.
Management of alcohol
withdrawal
ALC 2 & ALC 3. Supported withdrawal from alcohol should be advised in patients with alcohol dependence.
Benzodiazepines are recommended as front-line medication for the management of alcohol withdrawal in alleviating
withdrawal discomfort, and preventing and treating seizures and delirium. Antipsychotic medications should not be used as
stand-alonemedications for themanagement of alcohol withdrawal. They should only be used as an adjunct to benzodiazepines
in severe withdrawal delirium that has not responded to adequate doses of benzodiazepines.
Anticonvulsants should not be used following an alcohol withdrawal seizure for the prevention of further alcohol withdrawal seizures.
Psychoactive medication used for the treatment of alcohol withdrawal should be dispensed in small quantities, or each dose
supervised, to reduce the risk of misuse.
Patients at risk of severe withdrawal, or who have concurrent serious physical or psychiatric disorders, or who lack adequate
support, should preferably be managed in an inpatient setting.
As part of withdrawal management, all patients should be given oral thiamine. Patients at high risk (malnourished, severe
withdrawal) or with suspected Wernicke’s encephalopathy should be given parental thiamine.
Preventing relapse in alcohol
dependent patients
ALC 4. Acamprosate, disulfiram, or naltrexone should be offered as part of treatment to reduce relapse in alcohol dependent
patients. The decision to use acamprosate, disulfiram, or naltrexone should be made taking into consideration patient
preferences, motivation, and availability.
Psychosocial interventions
for management of alcohol
dependence
ALC 5. Psychosocial support should be routinely offered to alcohol dependent patients. Where providers have capacity, more
structured psychological interventions, such as motivational techniques, should be considered.
Non-specialist health care providers should consider involving family members in the treatment of the patient with alcohol
dependence, where appropriate, and offer support to family members in their own right.
Role of mutual help groups
such as Alcoholics Anonymous
(AA)
ALC 6. Non-specialist health care workers should familiarize themselves with locally available mutual help groups (such as Alcoholics
Anonymous), and should encourage the alcohol dependent patient to engage with such a group. They should monitor the impact of
attending the group on the patient with alcohol dependence.
Family members of patients with alcohol dependence should also be encouraged to engage with an appropriate mutual help
group for families.
doi:10.1371/journal.pmed.1001122.t006
Table 7. Abridged recommendations for drug use disorders (DRU 1–6).
Brief psychosocial interventions DRU 1. Individuals using cannabis and psychostimulants should be offered brief intervention, which should comprise
a single session of 5–30 minutes in duration, incorporating individualized feedback and advice on reducing or
stopping cannabis/psychostimulant consumption, and the offer of follow up.
People with ongoing problems related to their cannabis or psychostimulant drug use who do not respond to brief
interventions should be considered for referral for specialist assessment.
Management of drug withdrawal DRU 2. Withdrawal from cannabis, cocaine, or amphetamines is best undertaken in a supportive environment. No
specific medication is recommended for the treatment of their withdrawal.
Relief of symptoms (e.g., agitation, sleep disturbance) may be achieved with symptomatic medication for the period
of the withdrawal syndrome. Less commonly, depression or psychosis can occur during withdrawal; in these cases the
individual needs to be monitored closely and advice sought from relevant specialists, if available.
Withdrawal from benzodiazepines is best undertaken in a planned (elective) manner, using a gradually tapering dose
over 8–12 weeks and with conversion to long-acting benzodiazepines, rather than using short-acting ones. Additional
psychosocial support should be considered. If a severe benzodiazepine withdrawal syndrome develops, specialist
advice should be obtained regarding starting a high-dose benzodiazepine sedation regime and hospitalization.
Treatment of psychostimulant
dependence
DRU 3. Dexamphetamine should not be offered for the treatment of stimulant use disorders.
Psychosocial support for the management
of cannabis dependence and abuse and
psychostimulant use disorders
DRU 4 & DRU 5. Short duration psychosocial support modeled on motivational principles should be offered for the
treatment of cannabis use disorders and psychostimulant use disorders in non-specialized settings.
Individuals with these disorders who do not respond to short duration psychological support may be referred for
treatment in a specialist setting, when available.
Role of sterile injection equipment and
outreach programmes for injecting
drug users
DRU 6. In communities with a high prevalence of drug injection, primary health care providers should facilitate the
provision of sterile injection equipment and retrieval of used equipment in primary care centres through involvement of
community pharmacies or through outreach programmes.
If resources allow, outreach programmes should be implemented to facilitate access to sterile injecting equipment (and
retrieval), information, health care (including testing and counseling for HIV, and hepatitis), and entry to drug treatment.
doi:10.1371/journal.pmed.1001122.t007
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practice. However, it is very difficult for
the individual health care provider to
interpret the existing evidence coming
from randomized controlled trials, obser-
vational studies, and other sources of
scientific evidence. Even if the evidence
is systematically reviewed, the translation
into the relevant policy and programme
decisions, as well as the implementation in
practice, is not straightforward. Effective
strategies, techniques, and incentives are
needed to disseminate and implement the
guidelines. Finally, the interventions need
to be adopted and integrated into practice
by providers at all levels [13].
In the field of mental health care, the
issue of how guidelines should be imple-
mented to maximize their impact on
clinician performance and patient out-
come has rarely been investigated. A
recent meta-analysis of different guideline
implementation strategies included only
18 studies, nine of which were randomized
trials [14]. The analysis of these 18 studies
revealed that multifaceted interventions
were more likely to have an impact on
clinician performance and patient out-
come, albeit effect sizes were generally
modest. Additionally, it has been shown
that audit of clinical activities and feed-
back to doctors may be a relevant
component of any implementation strate-
gy [15]. These findings are in line with
those of a landmark systematic review of
implementation studies [16].
The scarce evidence base on how
guidelines should be implemented must
not weaken international efforts to develop
and evaluate implementation plans [17].
As part of the WHO implementation
strategy, mhGAP recommendations have
been incorporated into an integrated
package of interventions called mhGAP
Intervention Guide (mhGAP-IG) for Mental,
Neurological and Substance Use Disorders in
Non-specialized Health Settings [18]. The
mhGAP-IG translates the evidence-based
recommendations into simple clinical pro-
tocols and algorithms to facilitate decision
making for assessment and management.
It is aimed at non-specialist health care
providers working at first- and second-
level facilities. It is important that they are
trained and then supervised and supported
by the specialists.
The mhGAP-IG provides an integrat-
ed package of interventions for the
management of priority MNS disorders.
The reasons for integrated packages are
the following: one, packages are an
effective and efficient way of improving
health service delivery. Two, delivery of
interventions as a package is relatively
Table 8. Abridged recommendations for child and adolescent mental health conditions (CAMH 1–13).
Maternal mental health
interventions
CAMH 1. For at-risk children, parenting interventions promoting mother–infant interactions, including psychosocial stimulation,
should be offered to improve child development outcomes. To improve child development outcomes, mothers with depression
or with any other mental, neurological or, substance use condition should be treated using effective interventions (see
recommendations for treatment of depression and other mental, neurological, or substance use conditions).
Parent skills training
for behavioural disorders
CAMH 5. Parent skills training should be considered for the treatment of emotional and behavioural disorders in
children aged 0–7 years. The content should be culture sensitive but should not allow violation of children’s basic
human rights according to internationally endorsed principles.
Parent skills training for
developmental disorders
CAMH 6. Parent skills training should be considered in the management of children with intellectual disabilities and
pervasive developmental disorders (including autism). Such training should use culturally appropriate training material.
Child abuse CAMH 2. Non-specialized health care facilities should consider home visiting and offer parent education to prevent
child abuse, especially among at-risk individuals and families. They should also collaborate with school-based ‘‘sexual
abuse prevention’’ programmes where available.
Intellectual disabilities CAMH 3. Non-specialized health care providers should consider assessment and regular monitoring of children
suspected of intellectual and other developmental delays by brief, locally validated questionnaires. Clinical assessment
under the supervision of specialists to identify common causes of these conditions should be considered.
CAMH 4. Non-specialized health care providers should consider supporting, collaborating with, and facilitating referral
to and from community-based rehabilitation programmes.
Behaviour disorders (attention
deficit hyperactivity disorder
[ADHD])
CAMH 7. Non-specialized health care providers at the secondary level should consider initiating parent education/
training before starting medication for a child who has been diagnosed as suffering from ADHD. Initial interventions
may include cognitive behavioural therapy (CBT) and social skills training if feasible.
Methylphenidate may be considered, when available, after a careful assessment of the child, preferably in consultation
with the relevant specialist and taking into consideration the preferences of parents and children.
Pharmacological interventions for
children with disruptive behaviour
disorders or conduct disorder or
oppositional defiant disorder
CAMH 8. Pharmacological interventions (such as methylphenidate, lithium, carbamazepine, and risperidone) should not
be offered by non-specialized health care providers to treat disruptive behaviour disorders (DBD), conduct disorder
(CD), oppositional defiant disorder (ODD), and comorbid ADHD. For these conditions, the patients should be referred
to a specialist before prescribing any medicines.
Somatoform disorders CAMH 9. Pharmacological interventions should not be considered by non-specialized health care providers. Brief
psychological interventions, including CBT, should be considered to treat somatoform disorders in children, if adequate
training and supervision by specialists can be made available.
Antidepressants for children
with depression
CAMH 10. Antidepressants should not be used for the treatment of children 6–12 years of age with depressive episode/
disorder in non-specialist settings.
Antidepressants for adolescents
with depression
CAMH 11. Fluoxetine, but not tricyclic antidepressants (TCA) or other selective serotonin reuptake inhibitors (SSRI), may
be considered as one possible treatment in non-specialist settings of adolescents with depressive episodes.
Adolescents on fluoxetine should be monitored closely for suicide ideas/behaviour. Support and supervision from a
mental health specialist should be obtained, if available.
Pharmacological interventions for anxiety
disorders in children and adolescents
CAMH 12. Pharmacological interventions should not be considered in children and adolescents with anxiety disorders
in non-specialist settings.
Behaviour change techniques for
promoting mental health
CAMH 13. Non-specialized health care facilities should encourage and collaborate with school-based life skills
education, if feasible, to promote mental health in children and adolescents.
doi:10.1371/journal.pmed.1001122.t008
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cost-effective in terms of training and
supervision. Many interventions and
conditions go naturally together because
they can be delivered by the same person
at different times and because a limited
range of interventions are applicable to a
variety of conditions. Three, packages
help concentrate scarce resources on the
services that provide the best ‘‘value for
the money’’. We believe that the imple-
mentation of mhGAP guidelines and
scaling them up would lead to a decrease
in the burden of MNS disorders. For
example, 7 million DALYs (11% of
burden due to depression) are avertable
with 50% coverage with interventions for
depression (anti-depressant drugs [gener-
ic TCAs or SSRIs] plus brief psycho-
therapy) [19]. Similarly, 23% of burden
due to epilepsy is avertable at 50%
coverage with standard antiepileptic
drugs [20]. Thus, the gains that are
possible from scaling up of the integrated
package could be substantial.
Although the mhGAP-IG is the princi-
pal clinical tool being used as part of the
scaling up strategy of the mhGAP pro-
gram in countries, accompanying training
materials are being developed for capacity
building. Program implementation using
the mhGAP-IG has already started in
four countries: Ethiopia, Jordan, Nigeria,
and Panama [21]. There are a number of
major implementation research questions
that now need addressing. mhGAP has
provided a definitive platform to define
‘‘what’’ should be scaled up. The ‘‘how’’
question needs answering now. An exam-
ple of such an initiative is the multi-
Table 9. Clinical practice implications of mhGAP recommendations.
Clinical Practice Evidence mhGAP Recommendation
Patients with depressive symptoms, but
without moderate or severe depression,
are frequently treated with antidepressants.
In people with depressive symptoms (in absence of
depressive episode/disorder), there is unlikely a clinically
important difference between antidepressants and
placebo [23]. In people with current depressive episode/
disorder, available evidence suggests that the
drug–placebo differences for antidepressants increase
as a function of initial severity, rising from virtually no
difference in mild depression to a small difference for
adults with moderate depression and a medium
difference in severe depression [24].
Antidepressants should not be considered for
the initial treatment of adults with depressive symptoms
in absence of current/prior moderate or severe
depressive episode/disorder.
Combination of antipsychotic and
anticholinergic medicines is commonly used.
There is no evidence supporting routine use of
anticholinergic drugs [25].
Anticholinergics should not be used routinely for
preventing extrapyramidal side effects.
EEG is commonly used to confirm or exclude
diagnosis of epilepsy in individuals with
suspected seizures.
EEG is a diagnostic test with variable sensitivity and
specificity [26]. It may be normal in people with
epilepsy and can be abnormal in normal people. In
addition, technical and interpretative standards need
to be met.
Overinterpretation of EEG and misdiagnosis of
epilepsy is an important problem [27,28].
EEG and neuroimaging should not be used routinely
for diagnosis of epilepsy and starting treatment in non-
specialized health care settings in low and middle
income countries.
Treatment of alcohol dependence has, in
many settings, been considered something
that needs the support of a specialist treatment
service. Many primary care services are reluctant
to get involved in the treatment of alcohol
dependence themselves.
Medications such as acamprosate and naltrexone are
effective in primary care and result in significantly
improved treatment outcomes. Disulfiram is also
effective, and can also be used in primary care, with
specialist support if needed [29].
Acamprosate, disulfiram, or naltrexone should be offered as
part of treatment to reduce relapse in alcohol dependent
patients. The decision to use acamprosate, disulfiram, or
naltrexone should be made taking into consideration patient
preferences, motivation, and availability.
Inappropriate diagnosis of ADHD and use of
stimulants have often been described,
raising concerns when the treatment is
offered by non-specialized health providers.
Parent training, cognitive-behavioural therapy, and
social skills have been shown to be effective for ADHD
[30,31]. Methylphenidate has been shown to be
effective for reducing hyperactivity and improving
quality of life. And despite treatment acceptability
limitations and side effects, it has been recommended
for treating ADHD [30–32].
Non-specialized health care providers at the secondary level
should consider initiating parent education/training before
starting medication for a child who has been diagnosed as
suffering from ADHD. Initial interventions may include CBT
and social skills training if feasible.
Methylphenidate may be considered, when available, after a
careful assessment of the child, preferably in consultationwith
the relevant specialist and taking into consideration the
preferences of parents and children.
Off-label prescribing of antipsychotic drugs
has been commonly employed to treat
symptoms of aggression, agitation, and
psychosis in patients with dementia.
The evidence review suggests that these drugs appear
to have only a limited positive effect in treating these
symptoms but can cause significant harm to people with
dementia [33].
Thioridazine or chlorpromazine should not be used for the
treatment of behavioural and psychological symptoms of
dementia. Haloperidol and atypical antipsychotics should not
be used as first line management. Where there is clear and
imminent risk of harm with severe and distressing symptoms,
their short-term use may be considered, preferably in
consultation with a specialist.
Psychiatric or psychological assessment or
help besides the treatment of somatic
symptoms does not include systematic
assessment of suicide ideas.
Evidence of priority conditions, chronic pain, and
emotional distress being associated with suicide.
Evidence that asking about suicide ideas or thoughts
does not increase the risk of committing suicide [34,35].
Persons suffering from any of the other priority conditions or
who present with chronic pain or acute emotional distress
should be asked about thoughts, plans, or acts of self-harm.
Specialist services for drug use disorders are
difficult to access in many countries. Non-specialists
often do not feel confident to discuss drug
problems with drug users.
Brief psychosocial interventions are effective in
reducing cannabis and psychostimulant use. These
brief interventions can be delivered by non-specialists
by engaging the person using drugs in a short structured
discussion incorporating motivational principles [36].
Short duration psychosocial support modeled on
motivational principles should be offered for the treatment of
cannabis use disorders and psychostimulant use disorders in
non-specialized settings.
doi:10.1371/journal.pmed.1001122.t009
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partner PRogramme for Improving Men-
tal health carE (PRIME) Project, which
has the objective to generate evidence on
the implementation and scaling up of
treatment programmes for priority mental
disorders in low-resource settings [22]. In
the near future, further efforts should be
made to introduce formal evaluations of
the capability of these programs to induce
relevant and persistent changes, and to
generate useful insights on how imple-
mentation in LAMIC should be conduct-
ed to maximize benefit at sustainable
costs.
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